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Patients with chronic inflammation are often associated with the emergence of
depression symptoms, while diagnosed depressed patients show increased levels of
circulating cytokines. Further studies revealed the activation of the brain immune cell
microglia in depressed patients with a greater magnitude in individuals that committed
suicide, indicating a crucial role for neuroinflammation in depression brain pathogenesis.
Rapid advances in the understanding of microglial and astrocytic neurobiology were
obtained in the past 15–20 years. Indeed, recent data reveal that microglia play
an important role in managing neuronal cell death, neurogenesis, and synaptic
interactions, besides their involvement in immune-response generating cytokines. The
communication between microglia and neurons is essential to synchronize these diverse
functions with brain activity. Evidence is accumulating that secreted extracellular vesicles
(EVs), comprising ectosomes and exosomes with a size ranging from 0.1–1 µm, are
key players in intercellular signaling. These EVs may carry specific proteins, mRNAs and
microRNAs (miRNAs). Transfer of exosomes to neurons was shown to be mediated by
oligodendrocytes, microglia and astrocytes that may either be supportive to neurons,
or instead disseminate the disease. Interestingly, several recent reports have identified
changes in miRNAs in depressed patients, which target not only crucial pathways
associated with synaptic plasticity, learning and memory but also the production of
neurotrophic factors and immune cell modulation. In this article, we discuss the role of
neuroinflammation in the emergence of depression, namely dynamic alterations in the
status of microglia response to stimulation, and how their activation phenotypes may
have an etiological role in neurodegeneneration, in particular in depressive-like behavior.
We will overview the involvement of miRNAs, exosomes, ectosomes and microglia in
regulating critical pathways associated with depression and how they may contribute to
other brain disorders including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease
(AD) and Parkinson’s disease (PD), which share several neuroinflammatory-associated
processes. Specific reference will be made to EVs as potential biomarkers and disease
monitoring approaches, focusing on their potentialities as drug delivery vehicles, and
on putative therapeutic strategies using autologous exosome-based delivery systems
to treat neurodegenerative and psychiatric disorders.
Keywords: astrocytes, exosomes, ectosomes, microglia, neurodegeneration, glia interplay, oligodendrocytes,
microRNAs
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INTRODUCTION
Depression (major depressive disorder, MDD) is a mood
disorder of multifactorial origin, including genetic and
environmental factors, estimated to affect 350 million people
worldwide (Jo et al., 2015). It is responsible for increased
morbidity and mortality, adverse health behaviors, lost work
productivity and increased health care utilization (Benton et al.,
2007). Suicide accounts for almost 1 million lives lost each year,
i.e., 3000 suicide deaths per day (World Health and Organization,
2012). About 25% of people diagnosed with MDD are under 19
years old and about 40% of patients do not adequately respond
to current therapy (Dwivedi, 2014). To that it may account the
poor understanding of the underlying mechanisms leading to
MDD and suicidal behavior.
Stress, impaired neurogenesis and defects in synaptic
plasticity represent three interconnected factors that are
associated with depression (Dwivedi, 2011; Mouillet-Richard
et al., 2012). Characteristic pathophysiological hallmark
features include monoamine depletion, down-regulation of
neurotrophin signaling, and glucocorticoid receptor (GR)
resistance, as well as excess of glutamate, corticotrophin-
releasing hormone and cortisol levels (Carvalho et al., 2015;
Jo et al., 2015). Stress has been associated to the development
of clinical depression, and evidence from preclinical studies
suggests a role of microglia in depression and stress.
Most curious, chronic stress has been known to promote
microglial hyper-ramification and astroglial atrophy (Tynan
et al., 2013), as well as lower immunoreactivity of myelin
basic protein (MBP) and fewer mature oligodendrocytes
(Yang et al., 2015) in the prefrontal cortex of rodents.
Other molecules that are gaining attention in depressive
pathophysiology are the cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB) involved
in learning and memory, whose expression is decreased in
depressed patients, and the vascular endothelial growth factor
(VEGF), an angiogenic cytokine, with decreased mRNA
levels in peripheral leukocytes of such individuals (Dwivedi,
2009).
As mentioned above, stress is a major risk factor for
depression leading to the activation of hypothalamus-pituitary-
adrenal (HPA) axis, as well as to a reduced hippocampal
neurogenesis, together with impaired hippocampal synaptic
plasticity and morphological neuroplasticity. Post-mortem
studies revealed unique pathological alterations in neuronal
and glial cells in the dorsolateral prefrontal cortex of patients
with MDD, in particular a reduced cell size and density
(Stockmeier and Rajkowska, 2004). Astrocyte deficits such
as a decreased cell number of glial fibrillary acidic protein
(GFAP)—immunoreactive cells and oligodendrocyte pathology,
probably related to disruptions of white matter tracts, were found
in depressed individuals (Rajkowska and Miguel-Hidalgo, 2007).
Abnormal activation of microglia, the immunologic guardian
cells of the brain, and increased microglial cell numbers were
observed in depression and in anxiety disorders, although it is
yet unclear how it relates with psychopathological conditions
(Serafini et al., 2015). To note that reactive glial cells are
sources and targets of various inflammatory cytokines, and as
so are involved in the regulation of neuroinflammation and
tissue repair (Rajkowska and Miguel-Hidalgo, 2007). Lately,
depression has been described as a microglia-associated
disorder, and besides the excessive cell activation and
increased cell number, microglia decline and senescence
was observed in some depressed patients as well (Yirmiya et al.,
2015).
Recent evidences suggest that extracellular vesicles (EVs)
secreted by neurons and glia, including endosome-derived
exosomes and fragments of the cellular plasma membrane play a
key role in intercellular communication and neuroinflammation
by transporting messenger RNA (mRNA), microRNA (miRNA)
and proteins (Pegtel et al., 2014). EVs are recognized as having
a role in pathogenesis and dissemination of inflammatory
diseases, besides their potential as biomarkers and therapeutic
vehicles (Buzas et al., 2014). Reactive microglia were shown
to release exosomes and microvesicles (MVs) carrying the
pro-inflammatory cytokine interleukin-1β (IL-1β), the IL-1β-
processing enzyme caspase-1, and the P2X7 receptor that may
induce and propagate inflammatory reactions throughout the
brain (Frühbeis et al., 2013).
A number of treatments were developed to increase the
availability of monoamines, such as serotonin, due to a
shift from serotonin to kynurenine pathway in tryptophan
catabolism. In the central nervous system (CNS) the kynurenine
pathway is mediated by astrocytes, microglia and infiltrating
macrophages (Jo et al., 2015). Current therapies usually
result in relapse rates of only 50%, reason why a better
understanding of the pathomechanisms involved in MDD may
help in the discovery of more effective and cost-effective
treatment alternatives. Accumulating evidence suggests that glial
pathology and the decrease in the number of glial cells are
prominent features in MDD (Hamidi et al., 2004; Altshuler
et al., 2010). Glial reduction in tissue samples from subjects
diagnosed with MDD, at least in amygdala, was shown to
be due to a loss of oligodendrocytes once no significant
changes were observed on microglia or astrocytes (Hamidi
et al., 2004). Patients with depression have been shown to
evidence increased serum levels of pro-inflammatory cytokines
that returned to normal by treatment with antidepressants
for 3 months (Dahl et al., 2014). Some studies revealed that
the reinforcement of neurotrophin expression and stimulation
of neurogenesis by causing antidepressant-like effects may
be of therapeutic relevance in chronically depressed patients
(Van Buel et al., 2015). These Authors argue that targeted
potentiation, instead of suppression of neuroinflammation, may
be of therapeutic relevance in chronic depressed patients.
Interestingly, electroconvulsive therapy of MDD was indicated to
facilitate the action of antidepressants by inducing hippocampal
neurogenesis through the modulation of microglial activation
(Rotheneichner et al., 2014). In addition, minocycline, which is
a suppressor of activated microglia, has been shown to exert
protective effects by reducing microglial activation, oxidative
stress and inflammation (Réus et al., 2015). Therefore, there
are some controversial hypotheses on the best therapeutic
approaches to MDD.
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This review article aims to summarize data about the effects
of immune system dysregulation and microglial activation on
mood dysregulation and will also discuss the role of EVs
and their specific cargo, namely miRNAs, as means by which
these neuroinflammatory mechanisms take place and influence
neighboring cells leading to the propagation of inflammation.
INFLAMMATION-ASSOCIATED
DEPRESSION
Chronic inflammation in physically ill patients is often associated
with the development of symptoms of depression (Benton et al.,
2007; Goldberg, 2010). Activation of the peripheral immune
system leads to increased cytokine levels that are actively
transported into the CNS stimulating astrocytes and microglial
cells, which in turn produce cytokines by a feedback mechanism
(Müller and Ackenheil, 1998). In such condition there is sickness
exacerbation and the development of symptoms of depression
in susceptible patients (Dantzer et al., 2008). Although not
completely clarified the intracellular molecular mechanisms
linking inflammation and depression, it was demonstrated that
microglia besides releasing inflammatory mediators also secrete
glutamate and metabolize kynurenine transported to the CNS
into quinolinic acid, a neurotoxic compound (Dantzer and
Walker, 2014). Astrocytes seem not to be able to uptake the excess
of glutamate that together with quinolinic acid will enhance
glutamatergic neurotransmission leading to the development
of symptoms of depression. Proinflammatory cytokines can
additionally stimulate HPA axis to release glucocorticoids
that supress neurogenesis (Liu et al., 2003). Recently, it was
suggested that neuroinflammation may not only derive from
pathological conditions, but also from enhanced neuronal
activity denominated as neurogenic neuroinflammation that may
aggravate stressful stimuli (Xanthos and Sandkuhler, 2014). How
inflammation decreases neurogenesis and leads to dysfunction of
neurotrophic system is scarcely understood as it is the cross-talk
between microglia, mostly associated to neuroinflammation, and
astrocytes that produce neurotrophins (Song and Wang, 2011).
It was observed that chronic unpredictable mild stress-
exposed rats, a well-documented model of depression, produced
increased IL-1β mRNA and protein levels in the prefrontal
cortex, which were not reproduced in serum or cerebrospinal
fluid (CSF). Nuclear factor kappa B (NF-κB) inflammatory
pathway and nucleotide binding and oligomerization domain-
like receptor family pyrin domain-containing 3 (NLRP3)-
inflammasome activation in microglial cells revealed to be
implicated (Pan et al., 2014). However, there are controversial
data on IL-1β alterations in periphery and CSF between
depressed animals and patients. In a meta-analysis study,
no changes were found for IL-1β, though elevated levels of
tumour necrosis factor (TNF)-α_and IL-6 were observed in
depressed subjects compared with control subjects (Dowlati
et al., 2010). In other studies, patients with depression showed
increased serum levels of IL-1β, IL-6, IL-8, IL-12 and TNF-α,
together with a decrease in IL-10 levels, an anti-inflammatory
cytokine (Schiepers et al., 2005; O’Brien et al., 2007; Song
et al., 2009). Actually, studies point to the activation of
inflammatory responses and to microglial P2X7, a purinergic ion
channel activated by ATP, as contributors to the pathogenesis
of depression (for review, see Stokes et al., 2015). Microglia
activation is particularly enhanced in individuals who committed
suicide and in depressive patients (Steiner et al., 2008; Schnieder
et al., 2014). In addition, suicide has been related not only to
microglial activation, but also to an increase of perivascular
macrophages around blood vessels (Torres-Platas et al., 2014). In
fact, stress has been linked to the development of both depression
and anxiety, with a key contribution of microglia activation, as
well as of recruitment of peripheral macrophages into the brain to
such events (Phillips et al., 2015; Réus et al., 2015). On the other
hand, the neuroinflammatory status associated with depression-
like symptoms may also result from the existence of peripheral
or central chronic inflammatory processes that continuously
activate peripheral macrophages, sending inflammatory signals
to the brain (Roman et al., 2013).
Hippocampus is a region with a high density of microglial
cells, especially in the CA1 region, and hippocampal microglial
activation demonstrated to be originated by stress and suggested
to be implicated in the pathophysiology of MDD, as well as
in other psychiatric and stress-related disorders (Walker et al.,
2013). Increased high mobility group box-1 (HMGB-1) protein
was demonstrated to be increased in the hippocampus of male
Sprague Dawley rats after tail shocks and to be responsible
for microglia priming by acting on the NLRP3 inflammasome
(Weber et al., 2015). In addition, low dose administration of
lipopolysaccharide (LPS) to mice, as a model of depression, led to
HMGB1 translocation from the nucleus to the cytoplasm, while
blockage of HMGB1 abrogated the depressive-like behavior
induced by LPS (Wu et al., 2015).
Magnetic resonance imaging findings in the chronic mild
stress (CMS) rodent animal, a model of depression, showed
demyelination signs at the bilateral frontal cortex, hippocampus
and hypothalamus, which revealed to be associated with
brain oedema and inflammation (El-Etr et al., 2015). Gene
expression profiling studies from patients with MDD showed
that genes involved in energy metabolism and mitochondrial
function were downregulated (Konradi et al., 2012), that
genes involved in immune response and inflammation were
upregulated (Shelton et al., 2011), and that genes expressed
in oligodendrocytes were downregulated (Aston et al., 2005).
These studies further corroborate the association between energy
impairment, inflammation and myelin loss during MDD.
Non-responders to depressive treatment have shown
increased baseline inflammation and oxidative stress
(Strawbridge et al., 2015; Vaváková et al., 2015). A recent
study evidenced that the antidepressant drug venlafaxine,
though not having any influence on the majority of microglia-
related proinflammatory parameters, significantly reduced
superoxide production while revealed a protective effect on
mitochondrial membrane potential, suggesting ability to prevent
the progression of depression (Dubovický et al., 2014).
Inflammation-associated depression is now considered a
clinical entity that provides an understanding on the dynamics of
interaction between peripheral and brain mechanisms (Dantzer
et al., 2011). Experimentally, acute immumostimulation by
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 December 2015 | Volume 9 | Article 476
Brites and Fernandes Microglia Activation, Microvesicles and miRNAs in Neuroinflammation-Depression
peripheral administration of LPS in mice caused sickness,
increased immobility in the tail suspension test and depressive-
like behavior in the forced swim test, together with a delayed
cellular activity (Frenois et al., 2007; O’Connor et al., 2009).
Some studies indicate that anti-inflammatory compounds in
patients with inflammatory disorders and depressed patients
may improve depressed mood, but conclusive data still waits
confirmation (Miller et al., 2009; Song and Wang, 2011).
It is still a matter of debate whether a chronic inflammatory
state may contribute to depression etiology or if inflammation
occurs as a consequence of a depressive state. As mentioned
above many stimuli related to depression may trigger microglia
activation, namely: (i) peripheral or central inflammatory
challenges; (ii) stress-related conditions derived from increase
of glucocorticoids via HPA axis, reported to activate microglia
(Sorrells and Sapolsky, 2007), from changes in gut microbiota,
shown to control the maturation and functioning of microglia
(Erny et al., 2015), or from psychological stress that promote
microglial activation through the release of alarmins within
the brain (Maslanik et al., 2013); and (iii) intense neuronal
activity. This activation, may then promote the suppression
of neurogenesis and neuroplasticity further enhancing the
development of depression-like symptoms, suggesting that a
prior inflammation may set the basis for the emergence of
depression. Furthermore, continuous activation of microglia
may concur to microglia function decline which have more
recently been observed in depressive patients (Hannestad et al.,
2013) and reported in several neurological conditions including
aging, Alzheimer’s disease (AD), and chronic stress which are
associated with a higher prevalence of MDD.
The study of cellular and molecular mechanisms of
inflammation-associated depression will open new possibilities
for developing new antidepressant compounds targeting
neuroinflammation or its downstream pathways. Nevertheless,
we should be cautious in believing that depression can be treated
by therapies targeting inflammation. Further studies are required
to evaluate whether a combined therapy with anti-inflammatory
compounds and antidepressants will result in additional clinical
benefits.
ROLE OF microRNAs IN DEPRESSION
MiRNAs are a class of small noncoding RNAs that are key
post-transcriptional regulators of gene expression, which may
impair the translation of their target mRNA or promote its
degradation, though they can on the contrary also act as
translation activators or even impair transcription by binding
to gene promoters (Krol et al., 2010; Younger and Corey,
2011). If we consider that more than 1400 miRNA genes were
already identified, that each one may target a high number
of different mRNAs, which individually can be suppressed by
multiple mRNAs, there is no doubt on their role as robust
determinants of cellular states (Krol et al., 2010; Rota et al., 2011;
Lin and Gregory, 2015). Most of miRNAs are transcribed as
pri-miRNAs by RNA polymerases II and III in the nucleus and
cut into pre-miRNAs by the Drosha complex (Mouillet-Richard
et al., 2012). Pre-miRNAs are transported to the cytoplasm by
exportin 5 and Ran GTPase for final processing by the RNAse
III enzyme Dicer generating 22 nt double-stranded mature
miRNAs with a 5′ phosphate end (Gregory and Shiekhattar,
2005; Ksiazek-Winiarek et al., 2013). The mature miRNA is then
incorporated into the RNA-induced silencing complex (RISC),
which become able to repress translation (O’Connor et al.,
2012).
Previous studies indicate that miR-124 and miR-128 are
primarily expressed in neurons, whereas miR-23, miR-26,
and miR-29 exist in large amount in astrocytes, supporting
a differential nature of expression (Smirnova et al., 2005).
Some miRNAs are associated with neurological functions such
as learning and memory and miR-132, -134, and -let-7 are
suggested to play a crucial role in the formation and plasticity
of synapses, and miR-124a and miR-125b have been associated
to the outgrowth of axons (Schratt et al., 2006; Le et al.,
2009; see Table 1). MiR-124 is the most abundant in the brain
and its dysregulation has been related with neurodegeneration,
neuroimmune disorders and CNS stress among others (for
review, see Sun et al., 2015). It was previously indicated to be a
key regulator of adult neurogenesis (Cheng et al., 2009) and one
of its targets is CREB (Rajasethupathy et al., 2009).
Also involved in neurogenesis is the miR-137 associated
with the development of neural stem cells into mature neurons
(Szulwach et al., 2010). Synaptic plasticity is a critical process in
learning and memory and its disruption may trigger psychiatric
disorders. Recent evidence suggests that neuronal plasticity
plays an important role in the recovery from depression and
brain derived-neurotrophic factor (BDNF) is a mediator of this
plasticity (Castrén and Rantamäki, 2010). Actually, BDNF was
found decreased in depressed patients and in stressed animals
(Dwivedi, 2009). In this context, miRNAs are known to influence
BDNF, which may in turn induce the synthesis of miR-132
to regulate neurogenesis (Castrén and Rantamäki, 2010; Yan
et al., 2013). The mitogen-activated protein kinases (MAPK)
superfamily, including the extracellular signal-regulated kinase
(ERK), c-Jun N-terminal kinase and p38 proteins, when activated
in microglia trigger the release of pro-inflammatory mediators
(Kaminska et al., 2009; see Figure 1), making MAPK signal
transduction crucial in regulating gene expression and mediating
a rapid response in stress-responsive microRNA expression
(Biggar and Storey, 2011). Expression of miR-221 and miR-222
was shown to be related with ERK1/2 activation (Terasawa et al.,
2009).
MiRNA expression was reported to be globally downregulated
in the prefrontal cortex of depressed suicide victims (Smalheiser
et al., 2012), which is consistent with the hypo-activation of
the frontal cortex reported in depressed subjects (Covington
et al., 2010). Those Authors observed that the 21 miRNAs
found downregulated were related to cell growth and
differentiation. However, miR-185 and miR-491-3p were
increased in the frontal cortex of suicide completers (Serafini
et al., 2014). Complementary studies using post-mortem
human prefrontal cortex samples from MDD patients showed
that miR-1202, a primate specific miRNA that is enriched
in the human brain, was down-regulated in depressed
individuals (Lopez et al., 2014). This miR-1202 targets the
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TABLE 1 | Critical and dysregulated microRNA (miR) in conditions of stress/depression.
microRNA Associated to depression-related pathways Directly implicated
in stress/depression
Reference
miR-1202
GRM4 as target. Modulator of glutamatergic,
dopaminergic, GABAergic and
serotonergic neurotransmission. Regulator of
anxiety-related behaviors.
↓ in the MDD patient’s brain Davis et al. (2012), Lopez
et al. (2014) and Rucker and
McGuffin (2014)
Let-7a Neuronal differentiation of embryonic neural
progenitors. Formation and plasticity of
synapses.
↑ in the frontal cortex following acute
stress
Schratt et al. (2006),
Schwamborn et al. (2009)
and Rinaldi et al. (2010)
miR-124 Important for neurogenesis. ↑ in the medial pre-frontal cortex
following maternal separation stress
Uchida et al. (2010)
miR-29a Targets Voltage Dependent Anion Channel and
ATP synthetase.
↑ in the medial pre-frontal cortex
following maternal separation stress
Uchida et al. (2010) and
Bargaje et al. (2012)
miR-26a Important in neuronal development and
morphogenesis.
↑ in the frontal cortex following acute
stress
Rinaldi et al. (2010) and Li
and Sun (2013)
miR-26b Induces cell cycle in postmitotic neurons and
apoptosis.
↑ in the frontal cortex following acute
stress
Rinaldi et al. (2010) and
Absalon et al. (2013)
miR-26b, miR-1972, miR-4485,
miR-4498, and miR-4743
Target biological processed involved in brain
development and function: axon guidance and
extension, synaptic transmission, learning and
memory.
↑ in peripheral blood mononuclear cells
from MDD patients
Fan et al. (2014)
miR-221-3p, miR-34a-5p, and
let-7d-3p
Target serotonin receptors, corticotrophin-
releasing hormone receptor and glutamate
transporters. Enrich pathways related to
neuronal function in depression.
↑ in serum from MDD patients Wan et al. (2015)
miR-451a ↑ in serum from MDD patients
miR-132 and miR-182 BDNF as target. ↑ in serum from depressed patients.
Polymorphism in the miR-182 gene is
associated with MDD.
Li et al. (2013) and Saus
et al. (2010)
miR-134 Can negatively regulate the size of dendritic
spines.
↑ in amygdala after owing acute stress Schratt et al. (2006) and
Meerson et al. (2010)
miR-183 Regulates the circadian-clock period. ↑ in amygdala after owing acute stress Xu et al. (2007) and
Meerson et al. (2010)
miR-1302 and miR-625 P2XR7 as target. Neuronal receptor involved
in synaptic transmission. Microglia scavenger
receptor involved in phagocytosis.
SNP in putative miRNA target sites
of miR-1302 and miR-625 of buccal
epithelial cells from MDD patients
Sperlágh et al. (2006),
Rahman et al. (2010) and
Gu et al. (2011)
miR-9 Controls dendritic growth and synaptic
transmission.
↑ in the frontal cortex following acute
stress and in the medial pre-frontal
cortex following maternal separation
Rinaldi et al. (2010), Uchida
et al. (2010) and Giusti et al.
(2014)
miR-144-5p Targets PKC, Wnt/β-catenin, and PTEN
pathways. Is involved in response to mood
stabilizer treatment and stress responses.
↑ in the plasma of depressed patients Zhou et al. (2009), Katsuura
et al. (2012) and Wang et al.
(2015)
BDNF, brain-derived neurotrophic factor; CSF, cerebrospinal fluid; GRM4, metabotropic glutamate receptor-4; PTEN, phosphatase and tensin homolog; PKC, protein
kinase C; P2XR7, purinergic receptor P2x, ligand-gated ion channel 7; SNP, single nucleotide polymorphisms.
expression of the gene encoding metabotropic glutamate
receptor-4 (GRM4), which was also up-regulated in MDD
patient samples. This receptor is localized pre- and post-
synaptically and functions as modulator of glutamatergic,
dopaminergic, GABAergic and serotonergic neurotransmission
(Pilc et al., 2008). More recently, it has been pointed
as a regulator of anxiety-related behaviors (Davis et al.,
2012).
A different study analyzed miRNAs in the peripheral blood
mononuclear cells (PBMCs) of MDD patient and identified that
5 miRNAs were up-regulated, such as miRNA-26b, miRNA-
1972, miRNA-4485, miRNA-4498, and miRNA-4743 (Fan et al.,
2014; see Table 1). The Authors next looked at predicted targets
of these miRNAs and identified genes with a wide variety
of biological effects, including axon guidance and extension,
synaptic transmission, learning and memory, which changes
have been associated to the pathophysiology of MDD. In
addition, another work evidenced that the plasma expression
of miR-144-5p was inversely associated with depression and
suggested its origin from the pathologic processes of depression
(Wang et al., 2015). MiR-144-5p is involved in the response to
mood stabilizer treatment (Zhou et al., 2009) and stress responses
(Katsuura et al., 2012), and target the protein kinase C (PKC),
Wnt/β-catenin, and phosphatase and tensin homolog (PTEN)
pathways (Zhou et al., 2009).
Several altered miRNAs were also identified in the CSF
of MDD patients but, notably, elevated miR-221-3p, miR-
34a-5p and let-7d-3p, together with low miR-451a levels in
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FIGURE 1 | Microglia activation with release of extracellular vesicles (EVs). In the healthy central nervous system, microglia have highly ramified morphology
with thin processes, which constantly monitor brain parenchyma to maintain the homeostasis. These microglia are commonly designated as surveillant microglia.
Upon stimuli, namely by the proinflammatory lipopolysaccharide (LPS), reactive or activated microglia acquire different morphologies from hypertrophic with enlarged
processes to an amoeboid shape. Intracellularly, several pathways become activated including the mitogen-activated protein kinases (MAPKs) superfamily,
comprising the c-Jun N-terminal kinase (JNK 1/2) and p38 proteins, which will trigger the activation of the nuclear factor-κB (NF-κB) and consequent induction of
first-line cytokine production, such as interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)-α. In parallel, microglia are also able to sense cellular/molecular debris
and intervene by phagocytosing them. Interestingly, messenger RNAs (mRNAs, curved symbols), microRNAs (miRNAs, black symbols) and cytokines (diamond-like
symbols) are selectively incorporated into multivesicular bodies (MVBs) and may be released from activated microglia encapsulated in EVs, comprising exosomes
and microvesicles. While exosomes are endocytic membrane-derived vesicles of small size (30–100 nm) that are contained in MVBs in the endosomal system and
secreted upon MVB fusion with the plasma membrane, microvesicles/ectosomes are quite large vesicles (100–1000 nm) that bud directly from the plasma
membrane. These vesicles will act as vehicles in cell-to-cell communication, being considered potential carriers of altered molecules promoting disease propagation.
serum, were suggested as potential biomarkers of MDD (Wan
et al., 2015). Among the 16 miRNAs identified part of them
were reported to be down-regulated during antidepressant
medications (miR-30a-5p, miR-34a-5p and miR-221; Zhou
et al., 2009). Analysis of their target genes showed that some
important genes related to MDD, such as serotonin receptors
(HTR2C), corticotrophin-releasing hormone receptor (CRHR1)
and glutamate transporters (SCL1A2), were down-regulated.
In contrast, diverse pathways linked to neuronal function in
depression, including axon guidance, Wnt signaling pathway,
neurotrophin signaling pathway, and long-term depression, were
associated to alterations in miR-451a, let-7d-3p, miR-221-3p and
miR-34a-5p in both serum and CSF. This study highlighted the
existence of differentially altered miRNAs in CSF and serum of
MDD patients and their modulation by antidepressant treatment
suggesting their potential use as biomarkers for MDD. Curiously,
overexpression of miR-34a, miR-30a-5p and let-7d were also
shown to down-regulate BDNF expression (Croce et al., 2013).
Data from a mouse model with learned helplessness—an
analog for depressive symptoms, demonstrated up-regulation
of a polycistronic miRNA cluster (including miR-96, miR-
182, and miR-183) that was shown to target genes in step
with the circadian clock (Xu et al., 2007). In accordance,
increased serum levels of miR-182 and also miR-132 were
also found in patients with depression (Xu et al., 2007). Most
attractive was the report that both miRNAs targeted BDNF,
which have also been detected at lower serum levels in patients
with depression (Pallavi et al., 2013). Recently, it was shown
that genetic variations in microRNA processing genes, namely
DGR8 and AG01 (variant AGOl rs636832), were associated
with depression (He et al., 2012). Therefore, given the role
of miRNAs as potential regulators of neurogenesis and neural
plasticity, and the studies suggesting that miRNA processing
polymorphisms may contribute to depression risk and response
to treatment (Dwivedi, 2014), it is anticipated that miRNAs
may constitute a diagnostic tool as well as targets to novel
medicines.
EXOSOMES AND ECTOSOMES AS
MEDIATORS OF NEUROINFLAMMATION
All neural cells, including neurons, astrocytes, oligodendrocytes
and microglia, release EVs comprising exosomes and ectosomes,
either in normal or pathological conditions (Gupta and Pulliam,
2014). For instance exosomes and ectosomes were shown to
be implicated in amyloid-beta (Aβ) cell-to-cell spreading and
neurotoxicity (Brites, 2015). In addition, proteins recruited to
exosomes were suggested to be linked to overexpression of
tau and associated to both toxicity and neurofibrillary lesion
spreading in AD (Saman et al., 2014). Lately, it was suggested that
increased incorporation of P-S396-tau, P-T181-tau, and Aβ1–42
in neurally derived blood exosomes predict the occurrence
of AD up to 10 years before clinical onset (Fiandaca et al.,
2015). Most curious tau dysfunction, in addition to the direct
effects of Aβ, may drive alterations in microglial phenotypes
and neuroinflammation (Metcalfe and Figueiredo-Pereira, 2010;
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Wes et al., 2014). This may justify why minocycline, an anti-
inflammatory agent, was shown to reduce neuroinflammation
and to restore cognition in an AD mouse model (Parachikova
et al., 2010).
Transfer of toxic proteins by exosomes include α-synuclein
with a concomitant increase in recipient cells factors that
is associated with Parkinson’s disease (PD) pathology and
progression, thus providing a suitable target for therapeutic
intervention (Alvarez-Erviti et al., 2011a; Bellingham et al.,
2012b). Moreover, it was demonstrated that α-synuclein can
induce an increase of microglia secreted exosomes containing a
high level of major histocompatibility complex (MHCs) class II
molecules and membrane TNF-α (Chang et al., 2013). Exosomes
derived from astrocytes and motor neurons also showed a key
role in the amyotrophic lateral sclerosis (ALS) disease based
on studies demonstrating the efficient transfer of mutant and
misfolded copper-zinc superoxide dismutase 1 (SOD1) to other
cells, reason why exosomes are now suggested as targets to
modulate ALS disease (Basso et al., 2013; Grad et al., 2014).
Aberrantly expressed cellular miRNAs, selectively packaged
and transported in exosomes, can lead to dysregulated gene
expression in the recipient cell (Gupta and Pulliam, 2014).
Exosomes released by prion-infected neuronal cells showed
increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,
miR-342-3p and miR-424 levels, together with reduced miR-
146a levels as compared to non-infected exosomes (Bellingham
et al., 2012a). Exosomes were associated to the pathogenesis of
infectious CNS diseases, prion disease, AD, PD and ALS (Brites
and Vaz, 2014; Gupta and Pulliam, 2014; Brites, 2015).
BIOGENESIS OF EXOSOMES AND
ECTOSOMES
Cells release into the extracellular environment several types
of membrane vesicles from endosomal and plasma membrane
origin designated by exosomes and MVs or ectosomes,
respectively (Raposo and Stoorvogel, 2013). These EVs, a
designation that was recommended for the two classes of vesicles
(Cocucci and Meldolesi, 2015), represent an important mode of
intercellular communication by serving as vehicles for transfer
and delivery of membrane and cytosolic proteins, lipids, mRNAs,
and microRNAs (miRNAs) between cells (Lin et al., 2015). EVs
are present in many if not all bodily fluids, including blood,
urine, saliva, amniotic fluid, breast milk and culture medium
of cell cultures (Théry et al., 2002, 2006). Since they contain
biologically active proteins and regulatory RNAs, they are
suggested to be associated with the propagation of a disease and
to create a microenvironment that may favor disease progression
(Vingtdeux et al., 2012; Kahlert and Kalluri, 2013).
EVs also include other denominations besides exosomes and
ectosomes, as shedding vesicles, nanoparticles, microparticles
and oncomes among others (Cocucci and Meldolesi, 2015).
Exosomes are endocytic membrane-derived vesicles of small size
(30–100 nm) that are contained in multivesicular bodies (MVBs)
in the endosomal system and secreted upon MVB fusion with
the plasma membrane (Prada et al., 2013; see Figure 1). MVs
observed by transmission electron microscopy pictures exhibit
characteristic cup-shaped or ellipsoid morphology (Momen-
Heravi et al., 2012; Fertig et al., 2014). Secretion of exosomes
derived from motor neuron-like NSC-34 cells overexpressing
mutant hSOD1G93A was proposed as a mechanism of cell-to-
cell transfer of mutant SOD1 toxicity (Gomes et al., 2007). These
cells indeed release with the characteristic cup-shape morphology
by transmission electron microscopy.
Although little is known about MVB fusion with the
plasma membrane, several Rab GTPases, including Rab5,
Rab27, and Rab35, were suggested to be involved (Shifrin
et al., 2013). Exosomal membranes are enriched in cholesterol
and sphingomyelin and certain membrane proteins, such
as tetraspanins and integrins (Frühbeis et al., 2012).
Exosome production may be inhibited by targeting neutral
sphingomyelinase-2 with GW4869 (Yuyama et al., 2012) or
manumycin-A that also showed to impair transfer of miRNAs
to other cells (Mittelbrunn et al., 2011). MVs/ectosomes are
quite large vesicles (100–1000 nm) that bud directly from the
plasma membrane (Turola et al., 2012; see Figure 1). The rate
of ectosome shedding is variable, with cells showing elevated
formation and release, and others a low rate of ectosome
formation (Cocucci and Meldolesi, 2011). Although there are
differences on the biogenesis of exosomes and ectosomes, the
two EVs display a similar function when released (Cocucci and
Meldolesi, 2015). CD63 and CD61 are indicated as markers
of exosomes and TyA and C1q of ectosomes, considering the
uncertainty of many others that have been appointed. The
time of release varies from delayed in exosomes to seconds in
ectosomes. Moreover, only 5% of exosomes have externalized
phosphatidylserine while MVs/ectosomes evidence a major
representation (Prada et al., 2013). The removal of plasma
membrane by ectocytosis is compensated by the fusion of MVBs
as a compensatory exocytic process of preformed intracellular
vesicles (Sadallah et al., 2011; Cocucci and Meldolesi, 2015).
ROLE OF VESICLES IN NEURON—GLIA
COMMUNICATION
Brain function depends on coordinated interactions between
neurons and glial cells that include microglia, astrocytes, and
oligodendrocytes. These cells release vesicles in a way regulated
by glutamate (Chivet et al., 2014), which participate in the
communication between those cells. EVs released from primary
cortical astrocytes and microglial cells appear to be triggered by
ATP-mediated activation of P2X7 receptors, after exposure of
phosphatidylserine at the cell surface, followed by downstream
stimulation of acid sphingomyelinase (Bianco et al., 2009).
Immature and reactive astrocytes in primary cultures were
shown to release large vesicles (up to 8 µm) from the cell
surface containing functional mitochondria and lipid droplets,
probably as a consequence of repetitive ATP stimulation
(Falchi et al., 2013). Vesicle delivery to the plasma membrane
involves interaction with the cytoskeletal microtubules and
actin filaments (Kreft et al., 2009). Astrocytes also release
smaller EVs with approximately 100 nm in size (exosomes;
Gosselin et al., 2013) containing both neuroprotective and
neurotoxic molecules. Astrocyte-derived MVs and exosomes
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were described to present neuroprotective proteins including
synapsin 1 (Wang et al., 2011), molecules implicated in
angiogenesis such as VEGF (Proia et al., 2008), and matrix
metalloproteinases involved in extracellular matrix proteolysis
(Sbai et al., 2010). Stressful events in astrocytes, like heat or
oxidative stress, were shown to induce the release of exosomes
carrying the heat shock protein 70 (Hsp70) and synapsin 1
with a pro-survival effect on neurons (Taylor et al., 2007).
Upon pathological conditions it has been suggested a detrimental
role of astrocyte-derived EVs in the propagation of pathogenic
proteins in the course of neurodegenerative disorders. Astrocytes
expressing SOD1 mutant, involved in familiar ALS, release
a higher amount of exosomes carrying this mutant protein,
which were shown to promote in vitro motor neuron death
following SOD1 efficient transfer (Basso et al., 2013). Further,
astrocytes exposed to Aβ species evidenced to secrete pro-
apoptotic exosomes which may be taken up by astrocytes
themselves or by other neighboring cells contributing to AD
neurodegeneration (Wang et al., 2012). Most attractive, it
was recently showed that the functional astrocytic excitatory
amino-acid transporter (EAAT)-1 is present in secreted EVs,
increasing its concentration upon astrocyte activation (Gosselin
et al., 2013), suggesting a possible role of this microvesicular
transporters in reducing excitotoxicity at an extracellular
level.
Oligodendrocyte-axon interaction constitutes a functional
unit allowing neuronal integrity (Nave, 2010). Oligodendrocytes
secrete exosomes in a calcium-dependent fashion containing
myelin proteins and lipids (Frühbeis et al., 2012). These
exosomes seem to convey autocrine signals (Bakhti et al., 2011),
but can also be internalized by microglia by micropinocytosis to
be degraded, thus avoiding an immune reaction (Fitzner et al.,
2011). Early studies suggest that oligodendrocyte exosomes may
play a crucial role in allowing the supply of myelin proteins (i.e.,
proteolipid protein and myelin oligodendrocyte glycoprotein),
heat-shock proteins, glycolytic enzymes and more recently
glycolytic substrates including lactate (Krämer-Albers et al.,
2007; Lee et al., 2012). Oligodendroglial exosomes may be
also internalized by neurons through endocytosis and their
cargo may contribute to neuroprotection and long-term axonal
maintenance (Frühbeis et al., 2012). Moreover, the release of
oligodendrocyte-derived exosomes seems to be modulated
through neuronal signaling (Frühbeis et al., 2013). Glutamate
release from neurons activates oligodendrocytes through
N-methyl-D-aspartate receptor (NMDA) engagement leading
to an increase of intracellular calcium and exosome secretion.
These exosomes are then internalized specifically by neurons,
and increased firing rate and altered gene expression upon
oligodendroglial exosome exposure was observed (Frohlich
et al., 2014), confirming that oligodendrocytes influence
neuronal physiology, either by induction of signaling cascades
or by transfer of mRNAs and miRNAs. Oligodendrocyte-
derived MVs have also been described to inhibit both
the morphological differentiation of oligodendrocytes and
myelin formation through neuronal modulation (Bakhti
et al., 2011), suggesting a sophisticated control of myelin
membrane biogenesis via MVs. As a physiological degradation
of oligodendroglial membrane, part of oligodendrocyte-derived
exosomes may be internalized by MHC class II negative
microglia through macropinocytosis being subsequently cleared
via the lysosomal pathway with no inflammatory response
(Fitzner et al., 2011). However, in pathological situations
such as AD, where activated microglia are associated with an
intense inflammatory milieu, oligodendrocytes were reported
to secrete EVs containing degraded myelin proteins (Zhan
et al., 2014). Upon stressful conditions, oligodendrocytes
may also release immune mediators and express known
chemoattractants, signifying an active role on microglia
activation and recruitment to the injured area (Peferoen et al.,
2014). Microglia activation and MV release will be the subject of
the next section.
Recent evidences indicate that exosomes from neuroblastoma
cells bind to neurons and glial cells, despite being preferentially
endocytosed by glia, while those released upon synaptic
activation bind selectively to other neurons (Chivet et al., 2014).
On the other hand, the release of serotonin from neurons was
evidenced to regulate microglia-derived exosomes involving the
elevation of intracellular calcium, at least under physiological
conditions, what suggests a neurotransmitter dependent release
(Glebov et al., 2015). Most curious, it was also demonstrated
that exosomes secreted by Schwann cells, the peripheral glial
cell type, are internalized by neurons increasing neurite growth
substantially and axonal regeneration (Lopez-Verrilli et al.,
2013). Most relevant, intercellular chaperone transmission
mediated by exosomes was demonstrated to contribute to
maintenance of protein homeostasis (proteostasis; Takeuchi
et al., 2015). Moreover, the secretion of harmful or unwanted
material in exosomes together with the autophagy-lysosomal
pathway also contribute to preserve intracellular protein and
RNA homeostasis (Baixauli et al., 2014).
Besides the biological roles of EVs in the CNS, these EVs
are also correlated with several neurological diseases, as already
indicated. To be noted that alterations in exosome composition
in some pathological conditions may switch the immunologically
inert exosomes into active ones triggering inflammatory
reactions in the CNS. EVs from oligodendroglioma cells
revealed to induce astrocyte cell death in primary cultures,
which was suggested to be mediated by the pro-apoptotic
effects of Fas ligand (FAS-L) and TNF-related apoptosis-
inducing ligand (TRAIL; Lo Cicero et al., 2011). Moreover,
it was mentioned that exosome-associated amyloids can act
as seeds for plaque formation contributing to AD (Rajendran
et al., 2014). Intriguingly, the transfer of miR-1 in EVs
from the glioblastoma cells was shown to induce multiple
changes in the glioblastoma multiform (GBM) surrounding
cells (Bronisz et al., 2014). Involvement of exosomes in
pathological processes is also associated with their role as
potential carriers of misfolded proteins (Bellingham et al.,
2012b; Russo et al., 2012; Schneider and Simons, 2013). Cell-
to-cell communication by exosomes has been related to the
PD progression. Neuronal exosomes containing α-synuclein
were suggested to be transmitted from neuron-to-neuron and
from neuron-to-glia, while those from activated glial cells to be
transferred in a glia-to-glia process, leading to disease spread and
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propagation of the inflammatory response, respectively (Russo
et al., 2012).
EXOSOMAL microRNA SIGNATURE
Cumulating data suggest that miRNAs are potential biomarkers
for the diagnosis and prognosis of a variety of diseases such as
cancer and neurological diseases (Mishra, 2014; Warnecke-Eberz
et al., 2015). Although no references associate exosomes with
depression syndromes, several reports highlight the involvement
of miRNAs and posttranscriptional dysregulation in psychiatric
disorders (see Table 1). One of the first association of depression
with altered miRNAs was described for P2RX7 (purinergic
receptor P2x, ligand-gated ion channel 7) gene, where single
nucleotide polymorphisms (SNPs) were identified in putative
miRNA target sites of miR-1302 and miR-625 within the P2RX7
3′-untranslated region (Rahman et al., 2010). P2RX7 channel is
involved in synaptic neurotransmitter regulation (Sperlágh et al.,
2006) and is present in microglia acting as a scavenger receptor
in the absence of its ligand ATP, mediating phagocytosis of
apoptotic cells and insoluble debris (Gu et al., 2011).
Recently, mRNAs and miRNAs were identified in exosomes
and showed to derive from an active sorting mechanism since
the miRNA profiling revealed that it may differ from that of
the cells of origin (Zhang et al., 2015). The latest exosome
content database identified 4563 proteins, 194 lipids, 1639
mRNAs, and 764 miRNAs in exosomes from multiple organisms
(Mathivanan et al., 2012). Electron microscopic analysis revealed
that microglia release exosomes with proteins already identified
in B cell- and dendritic cell (DC)3-derived exosomes, but with
unique proteins such as the aminopeptidase CD13 and the
lactate transporter MCT1, which may supply supplementary
energy substrate to neurons during synaptic activity (Potolicchio
et al., 2005; see Figure 2 for the typical protein composition
of exosomes derived from microglia). The Authors used the
N9 microglial cell line and analysis by mass spectroscopic
peptide mapping, Western blotting, and enzymatic analysis. They
found that N9-derived exosomes express specific markers of
late endosomes corroborating their organelle origin, as well as
MHC class II molecules and cathepsin S indicative of their
function as antigen presenting cells. Integrins involved in antigen
presentation and pattern recognition receptors important for
innate immunity were also detected.
Recent evidence suggests that miRNAs are transferred by
exosomes to recipient cells, while altering gene expression and
mediating functional properties (Valadi et al., 2007; Mittelbrunn
et al., 2011; Turchinovich et al., 2013; Weber, 2013). Exosomal
miRNA was indicated to be released via ceramide-dependent
secretory pathways controled by neutral sphingomyelinase that is
crucial for budding of intracellular vesicles into MVBs (Trajkovic
et al., 2008; Kosaka et al., 2010b; Kogure et al., 2011; Mittelbrunn
et al., 2011). However, the precise mechanisms of vesicular
miRNAs sorting and secretion are still to be clarified.
Since the majority of current reports describing isolation
of MVs-associated extracellular miRNA only rely on
ultracentrifugation, one should understand that such
experiments inevitably characterize miRNAs in a mixed
FIGURE 2 | Composition of typical microglial exosomes. Exosomes are
packed with several cellular components including messenger RNAs (mRNAs,
curved symbols), microRNAs (miRNAs, black symbols) and proteins.
Microglia-derived exosomes express specific markers of late endosomes
corroborating their organelle origin, as well as major histocompatibility
complexes (MHCs) class II molecules and enzymes (i.e., cathepsin S)
indicative of their function as antigen presenting cells, and integrins involved in
antigen presentation and pattern recognition receptors important for innate
immunity. Flotillin 1 is a membrane-associated protein that is enriched in
exosomes and thus commonly used as an exosomal marker. Tetraspanins are
a family of transmembrane proteins that become integrated in the membrane
of EVs and among them are CD9, CD63 and CD81, which are particularly
enriched in microglia-derived exosome. The surface-bound aminopeptidase
CD13 that degrades enkephalins and the lactate transporter monocarboxylate
transporter 1MCT-1 are also highly expressed in exosomes released from
microglial cells. CD14 is a monocyte/macrophage marker, regularly used to
characterize exosomal preparations. Extrusion of Na, K-ATPase is likewise
frequent in different populations of exosomes. Microvesicles also carry the
proinflammatory cytokine interleukin (IL-1β) that is shed from the plasma
membrane of the microglial cell upon ATP stimulation. In addition, exosomes
may additionally contain a distinct set of proteins, such as cytoskeletal proteins
and the glycolytic protein glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). The illustration is based on proteomic analysis of exosome
preparations derived from N9 microglial cells (Potolicchio et al., 2005).
population of MVs and exosomes (Turchinovich et al., 2013).
This is the case of a recent study identifying the presence
of miR-155 and miR-146a, two critical inflammation-related
miRNAs that showed to modulate microglia phenotype
(Cardoso et al., 2015), in exosomes that are released from
and taken up by dendritic cells (Alexander et al., 2015). The
Authors demonstrated that injection of miR-146a-containig
exosomes inhibited, while that of miR-155 promoted, the
endotoxin-induced inflammation in mice. Moreover, they
showed that one dendritic cell produces near 500 exosomes after
24 h of culture and that each one contains about one copy of
miR-146a.
It is presently considered that there are four main
processes for sorting miRNAs into exosomes: (i) The neural
sphingomyelinase 2-dependent pathway; (ii) The miRNA motif
and sumoylated heterogeneous nuclear ribonucleoproteins-
dependent pathway; (iii) The 3′-end of the miRNA sequence-
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dependent pathway; and (iv) The miRNA induced silencing
complex-related pathway (Zhang et al., 2015). It should be
considered that besides the involvement of specific sequences in
certain miRNAs in guiding their incorporation into exosomes,
sorting of exosomal miRNAs may be processed under the control
of enzymes or other proteins in a miRNA sequence-independent
manner (Khalyfa and Gozal, 2014).
Exosomal miRNAs have been indicated as a promising
platform for compartment biomarker and early detection of
diseases, including brain disorders (Cheng et al., 2014; Khalyfa
and Gozal, 2014; Hornick et al., 2015; Lin et al., 2015;
Schwarzenbach, 2015). Recent advances in the research of
exosomal biomarkers and their potential application in clinical
diagnostics will be addressed in the last section of this review.
MICROGLIA ACTIVATION AND
MICROVESICLE RELEASE
Emerging data indicate that activation of microglia is associated
to both secretion of soluble molecules and release of EVs into
the pericellular space. In the healthy CNS, microglia have highly
ramified morphology with thin processes, which dynamically
monitor the neural cell microenvironment for surveillance in
efforts to maintain homeostasis (Nimmerjahn et al., 2005;
Kettenmann et al., 2011; see Figure 1). Reactive or activated
microglia acquire several altered morphologies, including a
hypertrophic cell with enlarged processes, or an amoeboid shape
(reviewed in Gemma and Bachstetter, 2013). Depending on the
stimuli and on the extent of activation, microglia acquire several
phenotypes, being the M1 (inflammatory cell) and M2 subtypes
(pro-regenerative cells) the most commonly indicated (Brites and
Vaz, 2014).
The proinflammatory phenotype intends to protect and
repair the CNS from being damaged (Czeh et al., 2011; Chhor
et al., 2013; Brites and Vaz, 2014). However, excessive and
prolonged neuroinflammation can be cytotoxic and harmful (for
review, see Cherry et al., 2014). The M2 phenotype, or the
alternatively activated state, inhibits inflammation and works
to restore homeostasis. This phenotype may include different
subtypes: (i) M2a associated with the production of anti-
inflammatory cytokines and trophic factors (Colton, 2009); (ii)
M2b considered to be a combined M1/M2a subtypes (Brites
et al., 2015); and (iii) M2c associated with phagocytosis and
suppression of the innate immune system (Brites and Vaz,
2014). However, one should be cautious when considering
that M2 microglia is always advantageous, once it was
suggested to correspond to a deactivated, irresponsive population
(Chakrabarty et al., 2012), and M2a together with M2c cells
were shown to be implicated in AD progression in the APP/PS1
transgenic mice (Weekman et al., 2014). Actually, the notion
of microglia as either ‘‘good’’ or ‘‘bad’’ is believed to be too
simplistic because microglia switch between these phenotypes
and may exist in many intermediate states. Today it is also
believed that surveillant microglia is able to phagocytose spines
and apoptotic cells (Sierra et al., 2013). Further studies are
required to decipher the participation of microglia subtypes
in cell homeostasis and neuroinflammation under normal and
pathological circumstances.
Non-vesicular mechanisms of microglial secretion mediated
by connexin (Cx)43, Cx36, and P2X7 ATP channels are increased
in M1 microglia (Eugenín et al., 2003; Dobrenis et al., 2005;
Choi et al., 2007). Recent data have shown that reactive microglia
release EVs, which are implicated in communication with the
brain microenvironment (for review, see Prada et al., 2013).
MVs, but not exosomes, seem to contain the cytokine IL-1β
and its proform, together with pro-caspase-1, the inflammasome-
associated enzyme responsible for IL-1β maturation, when
microglia is stimulated by LPS (Bianco et al., 2005). Most
interesting, MVs derived from either M1 or surveillant microglia
were shown to modulate synaptic activity (Prada et al., 2013).
Recent studies evidenced that active synapses promote the
pruning of inactive ones by stimulating microglial phagocytosis
with exosomes (Bahrini et al., 2015).
Through these processes, microglia influence brain cell
functions, either by propagating inflammation and causing
neurodegeneration or by playing a neuroprotective role. Indeed,
it was demonstrated that MVs from reactive microglia induce an
inflammatory reaction in target cells (Verderio et al., 2012a) and
that α-synuclein treated microglia release activated exosomes,
triggering increased apoptosis and with a suggestive role in
the progression of PD (Chang et al., 2013). Microglia-derived
MVs were also shown to participate in AD neurodegeneration
by promoting the formation of soluble Aβ species and the
propagation of such toxic forms (Joshi et al., 2014). On
the other way, it was demonstrated that interferon (IFN)-γ
stimulated microglia release nutritive exosomes that conferred
protection to the neighboring cells (Pusic and Kraig, 2015).
The release of MVs, at least from macrophages, was shown
to be enhanced when cells are treated with ATP and when
polarized either in M1 or in M2 phenotypes. The content
of such MVS seems to be determined by the polarization
state in that nucleic acid content was shown to be specific
(Garzetti et al., 2013). Moreover, different stimuli may trigger
the release of MVs with distinct properties, as observed
with monocytes (Bernimoulin et al., 2009). Some studies
also evidence that induced and proliferative senescence is
associated with increased release of MVs, mainly exosomes
(Lehmann et al., 2008). Actually, exosome production and
secretion are altered during in vivo aging and in cancer,
and their cargo in miRNAs was suggested to contribute to
aging (Xu and Tahara, 2013). One may then assume that
activation lead to an increased release of MVs that may differ
on their cargo and be associated with several physiological
and pathological processes in which neuroinflammation play
a pivotal role. Moreover, microglial decline and senescence
was suggested to also be implicated in depression-associated
impairments such as neuroplasticity and neurogenesis (Yirmiya
et al., 2015). Recently, it was demonstrated two principal
mechanisms of transmembrane protein release from senescent
cells, one related with tumour necrosis factor receptor 1
(TNFR1) by ectodomain shedding and the other of the full-
length intercellular adhesion molecule 1 (ICAM1) through
MVs, probably exosomes (Effenberger et al., 2014). Interestingly
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while autophagy was shown to decrease with age, the release
of exosomes seems to be enhanced in senescent cells (Brites,
2015).
EXTRACELLULAR VESICLES
IN ADVANCED MEDICINE
EVs have been investigated in neurodegenerative diseases
as potential biomarkers, improving diagnosis and disease
monitoring, as well as vehicles for targeted delivery of
pharmacological compounds and gene therapies. Most attractive
is that each EV relies on its source cell. They share expression
level, presence, absence, mutation, copy number variation,
truncation, duplication, insertion, modification, sequence
variation, or molecular association of a given molecule being
defined as a bio-signature. According with this concept of EVs
bio-signature, analysis of EVs in circulating fluids may allow the
identification of their cellular source and constitute important
disease biomarkers, either in diagnosis or prognosis.
It has been proposed that serotonin dysfunctions are
implicated in the pathophysiology of MDD and decreased levels
were found in MDD patients (Paul-Savoie et al., 2011). Thus,
serotonin remains at the core of recent advances to elucidate
the underlying mechanisms of depression (Albert et al., 2012).
Most interesting serotonin was demonstrated to stimulate the
secretion of exosomes from microglia cells (Glebov et al., 2015).
We may speculate that low levels of serotonin in MDD patients
may influence the microglia release of exosomes and be related
with the pathology. Indeed, decreased exosome formation was
demonstrated to trigger Aβ aggregation for instance, reason
why exosome administration or enhancement of exosome
generation was suggested as a novel therapeutic approach to
AD (Yuyama et al., 2014). In the future, development of
engineered nanovesicles might be a valuable tool for the therapy
of pathologies associated with inflammation and oxidative stress,
including MDD. Future work on the role of exosomes in MDD is
required.
As previously noted exosomes may be used as delivery
platforms, encapsulating agents or siRNAs, but also as a
diagnostic tool due to their content in miRNAs and misfolded
proteins. The potential of miRNAs to serve as biomarkers in
a noninvasive manner for psychiatric and neurodegenerative
diseases and to monitor antidepressant response has been
progressing (Dwivedi, 2011, 2014; Serafini et al., 2012; Chana
et al., 2013; Dorval et al., 2013). Based on studies demonstrating
the role of miRNAs in neural plasticity, neurogenesis and
stress response, it is believed that they may contribute to the
pathogenesis and progression of MDD. For example, acute stress
and chronic stress induce an increase in the expression of selected
miRNAs, including miR-134, miR-183, miR-132, Let-7a-l, miR-
9–1, and miR-124a-l in the brain (for review, see Dwivedi, 2014).
Dysregulated miRNAs were observed in PBMCs from patients
with MDD and consistent overexpression along 8-weeks interval
was obtained for miR-941 and miR-589 (Belzeaux et al., 2012).
As already mentioned, actively secreted miRNAs are enclosed
in exosomes, which are excreted in response to stress signaling
(Mendell and Olson, 2012) and thus considered as potential
biomarkers in depression and antidepressant response (Dwivedi,
2014).
Exosomal miRNAs may constitute biomarkers of a specific
disease, as their serum levels are altered in a variety of
pathological conditions (Kosaka et al., 2010a; Etheridge et al.,
2011; Mo et al., 2012). Indeed, serum enrichment of exosomal
miR-21 was positively correlated with tumour progression
and aggressiveness in patients with oesophageal squamous cell
carcinoma (Tanaka et al., 2013), miR-19a with the recurrence in
human colorectal cancer (Matsumura et al., 2015) and miR-141
with metastatic prostate cancer (Kim and Kim, 2013). Increased
levels of serum exosomal miR-150, -155, miR-342 and -1246
may differentiate patients with acute myeloid leukemia (Fayyad-
Kazan et al., 2013; Hornick et al., 2015) and miR-122 can be an
indicator of liver injury and portal hypertension (Jansen et al.,
2015).
Brain exosomal miRNAs were shown to distinguish patients
with schizophrenia (increased expression of miR-497) from those
with bipolar disorder (increased expression of miR-29c; Banigan
et al., 2013). Brain-derived EVs can travel and be detected in
CSF (Verderio et al., 2012b) and based on the fact that they
cross the blood-brain barrier (BBB) from the periphery into the
brain (Gupta and Pulliam, 2014) we may hypothesize that the
opposite is also true. Therefore, a significant body of literature
indicate exosomes as novel biomarkers in clinical diagnosis
with high specificity and sensitivity derived from their excellent
stability, although their potential value in clinical diagnostics
still needs to be fully explored. Recent studies in PD provided
evidence on the existence of a circulating subpopulation of MVs
showing exosomal properties and enriched Integrin β1 content
(Tomlinson et al., 2015).
Nowadays it is considered that by engineering microglia
it will be possible to modulate derived EVs and redirect
microglia towards a neuroprotective phenotype able to
promote tissue repair and with promising therapeutic effects
in neurodegenerative diseases associated to inflammatory
processes. In particular, short interfering RNAs (siRNAs) are
now recognized as therapeutic tools that despite their poor
bioavailability can cross the BBB when administered by systemic
injection of target exosomes (Alvarez-Erviti et al., 2011b; El
Andaloussi et al., 2013). When purified exosomes were loaded
with exogenous siRNA by electroporation, strong mRNA and
BACE1 protein knockdown, a therapeutic target in AD, was
observed in wild-type mice (Alvarez-Erviti et al., 2011b). This
was the first demonstration of an exosome-based drug delivery
system. Furthermore, intracerebrally administered exosomes
revealed to act as potent scavengers for Aβ by carrying it on
the exosome surface, thus improving Aβ clearance what may
have potential benefits in AD (Yuyama et al., 2014). It was
additionally demonstrated that exosomes are able to transfer
siRNA to monocytes and lymphocytes triggering the silencing
of the target gene MAPK (Wahlgren et al., 2012) or knocking
down the target gene RAD51 in recipient cancer cells (Shtam
et al., 2013). It was shown that exosomes can also be loaded
with interference RNA (iRNA) and most curious, when injected
intravenously in mice they were identified only in the target cells
(Alvarez-Erviti et al., 2011b).
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There is a growing interest in exploring exosomes and their
cargo as a tool to monitor disease and as having therapeutic
potential as delivery vehicles for specific miRNAs and/or their
inhibitors (Kim et al., 2006; Bhatnagar et al., 2007; Lai et al.,
2011; Yang et al., 2011; Hu et al., 2012; Ohno et al., 2013). The
modulation of miRNA functioning may be achieved through
overexpression or by knocking down in EVs. As an example,
transfer of anti-miR-9 from mesenchymal stem cells (MSCs)
into GBM cells was able to reverse the chemoresistance by
blocking the expression of P-glycoprotein in GMB cells and
was mediated by the release of MVs (Munoz et al., 2013).
Exosomes are considered ideal for drug delivery due to the
low immunogenicity, capacity to transport molecules, ability
to interact with target cells and willingness to be manipulated
for personalized medicine (Gupta and Pulliam, 2014). Such
approach is of particular significance once the utilization of
miRNAs as therapeutics using a systemic approach needs to
overcome the gastrointestinal system, cross the BBB and produce
the desired effect in a specific part of the brain (O’Connor et al.,
2012).
There is a large body of information showing that
soluble factors and EVs within the secretome provide a
major contribution to paracrine activity generating a tissue
microenvironment that may be neurotoxic or beneficial to
regeneration. Secretome from NSCs and MSCs was shown to
contain NGF, glial derived neurotrophic factor (GDNF), and
BDNF, among others, and suggested to modulate the neurogenic
niche (Salgado et al., 2015). As the neurogenic process in the
adult brain constitutes a new dimension of plasticity, ways
to repair impairments in neuroplasticity may turn useful to
treat depression (Bessa et al., 2009; Mateus-Pinheiro et al.,
2013a,b). Other studies provided data showing that MSCs and
their secretome are able to rescue the AD cell model from
misfolded truncated tau-induced cell death (Zilka et al., 2011).
Therefore, another therapeutic option will be to inject the stem
cell secretome for repair of the damaged tissue, which may even
be improved through the use of gene expression methodologies
or culture preconditioning of modified stem cells increasing the
ability to secrete pro-regenerative factors (Drago et al., 2013).
EVs may be produced from stem cells and their cargo
modified to be enriched in growth factors, cytokines, chemokines
and regulatory miRNAs to achieve a faster and better
regeneration of the injured tissue (Ratajczak et al., 2012;
Drago et al., 2013). Most encouraging, EVs can be generated
from patient’s cells and used for autologous therapies after
modulation of their miRNA cargo. Although requiring a
great deal of future studies to understand how miRNAs are
transferred into exosomes and delivered to target cells, it is
expected that exosomes and/or ectosomes will be soon used in
clinics. Considering the link between neuroinflammation and
depression, we may assume that circulating exosomes from
activated glia may contain increased levels of MDD-related
miRNAs, which if modulated can switch exosomal neurotoxic
effects to neuroprotective activities. This is a field not yet
explored in MDD that deserves to be investigated in the future
inasmuch pathophysiology leading to mood disorders may differ
among patients.
FUTURE PERSPECTIVES
MDD is a disabling condition with impact on well-being and
a leading cause of disease burden in high-income countries.
Treatment of MDD is very challenging since some patients do not
respond to first-line pharmacotherapy. Current guidelines for the
management of MDD recommend selective serotonin receptor
inhibitors or serotonin-norepinephrine receptor inhibitors, but
due to side effects, including potential increased suicidal ideation,
clinicians are considering atypical antipsychotics as alternative
therapies. Augmentation of MDD patients that do not respond
adequately to antipsychotics has increased over the past decade.
Whether exosomes may help in the treatment of MDD deserves
additional research.
The need to target exact cell types with a specific treatment,
without changing the physiology of other cells or tissues, has
been one of the major challenges during the most recent
years. Furthermore, for in vivo application, there is also the
need to develop transport systems that cross major biological
barriers including the BBB. Under this concept, exosomes have
been postulated as potential new delivery vehicles for specific
miRNAs or their inhibitors (Kim et al., 2006; Bhatnagar et al.,
2007; Lai et al., 2011; Yang et al., 2011; Hu et al., 2012;
Ohno et al., 2013). Recent advances have been made to target
the brain using a systemic delivery route and to specifically
target immune cells in order to reduce neuroinflammation and
treat associated disorders as MDD. A link between immune
dysregulation and the pathophysiology of at least some forms
of major affective disorder has long been hypothesized and
abnormalities in peripheral cytokines in depressed patients
have led to propose a primary immunological etiology for
MDD (Eyre and Baune, 2012). While increased IL-6 was
observed to dysregulate genes involved in miRNA machinery,
IL-10 revealed neuroprotective properties in first episode
psychotic patients with depression (Noto et al., 2015). A better
understanding of the pathophysiology of MDD, mainly the
immune mechanisms, may help in selecting more powerful
biomarkers and discovering target effective treatments using
exosomes as delivering vehicles.
Neurons use glial cell exosomes to improve stress tolerance
by their role as multifunctional signal emitters. The low
levels of serotonin found in MDD patients (Jacobsen et al.,
2012) may compromise cell exosome release (Glebov et al.,
2015), establishing a bridge between MDD and the potential
role of exosomes in disease progression, either for not
releasing adequate growth factors and neurotransmitters or by
transporting inflammatory miRNAs. In addition, we should
consider that exosomes represent a mechanism to get rid of
toxic proteins having a neuroprotective action (Joshi et al.,
2015), but can also be mediators of neuroinflammation (Gupta
and Pulliam, 2014) by their cargo in miRNAs. Alvarez-Erviti
et al. (2011b) provided the proof-of-concept that exosomes
are a good delivery system of siRNAs to the mice brain.
The Authors showed that intravenously administered exosomes
derived from autologous murine dendritic cells are able
to knockdown specific proteins in neurons, microglia, and
oligodendrocytes in the brain of treated animals, proving the
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therapeutic potential of autologous exosome-based delivery
system. Most attractive, Bryniarski et al. (2013) recently showed
that exosomes can deliver their cargo into precise cell types in
antigen-specific manner by expressing on their surface specific
antibodies.
One preferential route of exosome administration into brain
tissue is intranasal delivery. An initial study showed that
exosomes derived from activated dendritic cells are efficiently
delivered by intranasal administration. They showed to be
preferentially taken up by oligodendrocytes and to improve
baseline myelination (Pusic et al., 2014), thus suggesting to be
a promising strategy for myelin-impaired disorders as MDD
(Rajkowska et al., 2015). Interestingly, modified exosomes
containing the signal transducer and activator of transcription
3 (Stat3) inhibitor JSI124, have previously been shown to
be specifically delivered to microglia cells via the intranasal
route, showing a significant protection from LPS-induced brain
inflammation (Zhuang et al., 2011).
Most attractively, recent studies showed that intraperitoneal
injection of the microglia inhibitor minocycline in adult mice
partially prevents LPS (Henry et al., 2008) or Interferon-α-
induced (Zheng et al., 2015) depressive-like symptoms. However,
studies on the use of non-steroid anti-inflammatory drugs
(NSAIDs; Jiang and Chang, 1999) or COX-1 inhibitor (Choi
et al., 2009), being COX-1 mainly activated in microglial cells,
reported an increase of depressive episodes in psychiatrically
healthy individuals. Moreover, a single administration of LPS
to severely depressed patients led to a short-term elevation
of first-line cytokines improving the depressed state in
the first 24 h (Bauer et al., 1995). This finding suggests
that the loss of microglia proper function, which may be
induced by a strong proinflammatory stimulus as LPS, may
also be in the basis of depression-like symptoms. So, it
may be hypothesized that deliver of microglia inhibitors or
microglia inducers (depending on the immune activation
state of the depressed patient) within vesicles targeting
microglia may result in promising therapeutic strategies for
MDD.
Overall, the production of EVs from patients’ own cells that
may be engineered to load specific miRNAs cargos and express at
cell surface known proteins to be recognized by specific cell types,
may in the future be an ideal strategy for personalized autologous
therapies. In addition, the induction of exosome release and cell-
to-cell communication for transmission of cytoprotective signals
may have additional benefits in some specific circumstances. One
could imagine combined therapy content in EVs targeting many
different sorts of natural MDD resistances at once. However, we
must not forget that a great deal of work must be performed
before such therapeutic approaches may become feasible in the
clinic for neurodegenerative and psychiatric disorders, including
MDD.
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